Clinical trials
NSCLC (Advanced Non-small Cell Lung Cancer) clinical trials
Below are recruiting nsclc (advanced non-small cell lung cancer) clinical trials, each written for real people, not researchers. We’re tracking 538 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06020430Recruiting
Skipping routine radiation for advanced lung cancer after immunotherapy and chemo
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
Wuhan, HubeiAges 18–75 - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Daphne, AlabamaAges 18 minutes+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Sacramento, CaliforniaAges 18 years+ - NCT06043817RecruitingPhase 1/Phase 2
Study of STX-721 for advanced lung cancer with EGFR or HER2 changes
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT06051695RecruitingPhase 1/Phase 2
CAR T cell therapy for mesothelin-positive solid tumors
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06068049Recruiting
Study of osimertinib in patients with EGFR-mutated lung cancer in Spain
This study is looking back at how people with EGFR-mutated non-small cell lung cancer who have taken osimertinib (Tagrisso) actually did in everyday medical care in Spain. It includes patients who took osimertinib in several different treatment scenarios.
A CoruñaAges 18 years+ - NCT06071013RecruitingPhase 1/Phase 2
Nintedanib plus EGFR inhibitor for EGFR-mutated lung cancer
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
TaichungAges 20–70 - NCT06073431Recruiting
Study on weight loss types in advanced cancer
This study looks at different types of weight loss (cachexia) in people with advanced lung, pancreatic, or colorectal cancer. Researchers want to find patterns to better understand and treat it. You can join even if you haven't lost weight yet.
Fort Smith, ArkansasAges 18 years+ - NCT06102057RecruitingPhase 2
PET-guided small volume chemoradiation with immunotherapy for lung cancer
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
DresdenAges 18 years+ - NCT06109558RecruitingPhase 1/Phase 2
LMV-12 plus Osimertinib for advanced lung cancer
This trial tests a new drug called LMV-12 combined with osimertinib for people with advanced non-small cell lung cancer that has certain genetic changes (MET amplification or RET fusion) and has stopped responding to standard EGFR inhibitor treatments.
Changsha, HunanAges 18 years+ - NCT06116786RecruitingPhase 1
Experimental drug JNJ-86974680 for advanced lung cancer
This study tests an experimental drug called JNJ-86974680 for people with advanced non-small cell lung cancer. It looks at how well the drug works, whether you have a gene change or not, and what treatments you've already had.
Newnan, GeorgiaAges 18 years+ - NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
Jonesboro, ArkansasAges 18 years+ - NCT06123754RecruitingPhase 3
Envafolimab plus chemo for stage III NSCLC before surgery
This trial tests a new immunotherapy (Envafolimab) combined with standard chemotherapy before and after surgery for stage III non-small cell lung cancer that can be removed. The goal is to see if adding Envafolimab helps shrink the tumor and improve outcomes compared to chemotherapy alone.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06127303RecruitingPhase 2
Toripalimab plus cryoablation for lung cancer with limited progression
This trial tests a combination of an immunotherapy drug (toripalimab) and a freezing treatment (cryoablation) for people with advanced non-small cell lung cancer that has started to grow again in only a few spots after initial treatment. It aims to see if this approach can help control the cancer without switching to a completely new therapy.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75 - NCT06147570RecruitingPhase 2
Study of HS-10365 for RET fusion-positive lung cancer
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06167460Recruiting
Blood test to monitor targeted therapy response in advanced lung cancer
This study uses a simple blood test to look at bits of tumor DNA (called circulating tumor DNA) to see how well your targeted therapy (TKI) is working. It helps doctors predict and monitor whether the treatment is effective for your advanced lung cancer.
Ho Chi Minh CityAges 18–80 - NCT06188650Recruiting
New drug combo for advanced lung cancer after two treatments fail
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Ningbo, ZhejiangAges 18 years+ - NCT06198868Recruiting
MRD blood test to guide treatment in lung cancer
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
Nanjing, JiangsuAges 18 years+ - NCT06205927RecruitingPhase 2
Carbon Ion Boost for Advanced Lung Cancer
This trial tests a new way to give radiation therapy (carbon ion boost) to people with advanced, inoperable lung cancer. The goal is to see if targeting the most aggressive parts of the tumor with a higher dose can improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT06225804RecruitingPhase 1
Study of ABSK112 for advanced non-small cell lung cancer
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
Beverly Hills, CaliforniaAges 18 years+ - NCT06228326RecruitingPhase 1/Phase 2
Study of KB707 for advanced cancers affecting the lungs
This trial tests a new medicine called KB707 for people with advanced cancers that affect the lungs. It uses a virus to deliver a gene that may help your immune system fight the tumor. The study is especially looking at people with lung cancer (NSCLC) or other solid tumors that have spread to the lungs and haven't responded to standard treatments.
Dothan, AlabamaAges 18 years+
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nsclc (advanced non-small cell lung cancer)?
- Yes. Clin2 currently lists 538 recruiting nsclc (advanced non-small cell lung cancer) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nsclc (advanced non-small cell lung cancer) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nsclc (advanced non-small cell lung cancer) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Advanced Non-squamous Non-small-cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.